NTRK1 and cancer: The most common co-altered pathways/genes were in the TP53 axis (TP53 or MDM2 genes) (70% of cancers); cell cycle (58%); PI3K pathway (55%); and receptor tyrosine kinases and MAPK pathway (65%).